Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 
Learn about the flu shot, COVID-19 vaccine, and our masking policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections PEDIATRICS Kimberlin, D. W., Lin, C. Y., Jacobs, R. F., Powell, D. A., Corey, L., Gruber, W. C., Rathore, M., Bradley, J. S., Diaz, P. S., Kumar, M., Arvin, A. M., Gutierrez, K., Shelton, M., Weiner, L. B., Sleasman, J. W., de Sierra, T. M., Weller, S., Soong, S. J., Kiell, J., Lakeman, F. D., Whitley, R. J. 2001; 108 (2): 230-238
Abstract
The objective of this investigation was to establish the safety of high-dose (HD) acyclovir for the treatment of neonatal herpes simplex virus (HSV) disease. In addition, an estimate of therapeutic efficacy was sought, both with respect to mortality and to morbidity. Virologic efficacy of HD acyclovir was also assessed.Infants who were
View details for Web of Science ID 000170211800022
View details for PubMedID 11483782